Open AccessEffectiveness of “Priorix” Against Measles and Mumps Diseases in Children Born After 2004 in the United Kingdom
Author(s) -
Michael Povey,
Emmanuel Aris,
Brigitte Cheuvart,
Gillian Hall,
Catherine Cohet,
Corinne Willame
Publication year - 2021
Publication title -
the pediatric infectious disease journal/the pediatric infectious disease journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.028
H-Index - 140
eISSN - 1532-0987
pISSN - 0891-3668
DOI - 10.1097/inf.0000000000003111
Subject(s) - measles , medicine , virology , pediatrics , environmental health , vaccination
Evidence on vaccine effectiveness (VE) may encourage vaccination and help fight the reemergence of measles and mumps in Europe. However, limited data exist on real-life effectiveness of individual measles, mumps and rubella (MMR) vaccines. This study evaluated VE of GSK's MMR vaccine ("Priorix") against measles and mumps.